Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients.

Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):9-15. doi: 10.1007/s00259-019-04529-8. No abstract available.

PMID:
31654093
2.

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2045-2054. doi: 10.1007/s00259-018-4079-z. Epub 2018 Jul 7.

3.

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R.

Urology. 1996 Aug;48(2):326-34.

PMID:
8753752
4.

Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.

Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M.

J Nucl Med. 2017 Jul;58(7):1081-1087. doi: 10.2967/jnumed.116.184457. Epub 2017 Feb 16.

5.

Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.

Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, Meller J, Thelen P.

EJNMMI Res. 2015 Dec;5(1):66. doi: 10.1186/s13550-015-0145-8. Epub 2015 Nov 17.

6.

Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?

Leitsmann C, Thelen P, Schmid M, Meller J, Sahlmann CO, Meller B, Trojan L, Strauss A.

Int Braz J Urol. 2019 May-Jun;45(3):459-467. doi: 10.1590/S1677-5538.IBJU.2018.0305.

7.

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.

Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T.

Eur Urol Oncol. 2018 May;1(1):78-82. doi: 10.1016/j.euo.2018.03.010. Epub 2018 May 15.

PMID:
31100231
8.

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209. doi: 10.1007/s00259-014-2949-6. Epub 2014 Nov 20.

9.

Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.

Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, Nguyen Q, Hickey A, Ihsheish N, O'Neill G, Horvath L, Chalasani V, Stricker P, Joshua AM.

J Nucl Med. 2019 Jul;60(7):950-954. doi: 10.2967/jnumed.118.223099. Epub 2018 Dec 14.

PMID:
30552200
10.

Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.

Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW.

Nucl Med Mol Imaging. 2017 Sep;51(3):202-211. doi: 10.1007/s13139-016-0439-4. Epub 2016 Aug 6. Review.

11.

Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.

Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.

Eur Urol. 2018 May;73(5):656-661. doi: 10.1016/j.eururo.2018.01.006. Epub 2018 Jan 19.

PMID:
29358059
12.

68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ.

J Nucl Med. 2017 Jan;58(1):81-84. doi: 10.2967/jnumed.116.181800. Epub 2016 Sep 22.

13.

PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.

Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, Hueper K, von Klot CA, Henkenberens C, Christiansen H, Thackeray JT, Ross TL, Bengel FM.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):913-922. doi: 10.1007/s00259-017-3924-9. Epub 2018 Jan 7.

PMID:
29308527
14.

The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.

Onal C, Guler OC, Torun N, Reyhan M, Yapar AF.

Eur J Nucl Med Mol Imaging. 2019 Nov 15. doi: 10.1007/s00259-019-04581-4. [Epub ahead of print]

PMID:
31732768
15.

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. doi: 10.1007/s00259-017-3711-7. Epub 2017 May 12. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Sep;44(10 ):1781.

16.

Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.

Natarajan A, Agrawal A, Murthy V, Bakshi G, Joshi A, Purandare N, Shah S, Puranik A, Rangarajan V.

World J Nucl Med. 2019 Jul-Sep;18(3):244-250. doi: 10.4103/wjnm.WJNM_47_18.

17.

Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.

Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber WA, Haberkorn U, Schwaiger M, Kratochwil C, Choyke P, Kramer V, Kopka K, Eiber M.

J Nucl Med. 2019 Mar;60(3):362-368. doi: 10.2967/jnumed.118.212233. Epub 2018 Jul 24.

18.

Current status of theranostics in prostate cancer.

Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):471-495. doi: 10.1007/s00259-017-3882-2. Epub 2017 Dec 28. Review.

19.

Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.

Chang SS, Reuter VE, Heston WD, Hutchinson B, Grauer LS, Gaudin PB.

Cancer. 2000 Jan 15;88(2):407-15.

PMID:
10640975
20.

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.

BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1. Erratum in: BMC Cancer. 2019 Jan 21;19(1):97.

Supplemental Content

Support Center